Project Grant K22CA282364
Award Date
8/1/24
Completion Date
7/31/27
Dollars Obligated
$194K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
This five-year $360,281 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will fund research under the Cancer Biology Research program (CFDA 93.396). The grantee, Washington University, will conduct studies to define the contribution of altered epigenetic patterns and genome organization to the pathogenesis of acute myeloid leukemia (AML). Researchers will perform comprehensive epigenetic analysis of DNA methylation and three-dimensional...
This $429,000 Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research (CFDA 93.395) federal grant program, supports research by Western University of Health Sciences to develop a novel chimeric antigen receptor (CAR) natural killer (NK) cell therapy that can specifically target acute myeloid leukemia (AML) with human leukocyte antigen (HLA)-DR loss. The goal is to create a dual CAR-NK cell that expresses an activating CAR against the AML antigen CD33 and...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $415,259 to the Rector & Visitors of the University of Virginia to conduct research on the role of long noncoding RNAs in acute myeloid leukemia (AML). The project aims to 1) determine the role of a specific regulatory RNA in primary and relapsed AML, and 2) define the mechanism underlying its deregulation in AML. This research will provide insights into how noncoding RNAs...
This federal Project Grant award, with the ID F30CA294723, was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program. The award of $107,052 to the Regents of the University of Minnesota aims to advance the understanding of tissue-resident adaptive CD56bright natural killer (NK) cell responses in cancer. The key objectives are to: 1) Determine whether the CD56bright "Bright-TANKS" NK cell population is associated with increased...
This $530,015 federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research conducted by the Fred Hutchinson Cancer Center in Seattle, WA to define how natural killer (NK) cells regulate the tumor microenvironment and enhance anti-tumor immune responses. The research aims to: Determine tumor-intrinsic features that regulate NK cell phenotype and function in the tumor; Define the mechanisms that regulate NK cell production of...
This Project Grant award of $458,698.00 was provided by the National Cancer Institute (NCI) under the federal Cancer Biology Research program (CFDA 93.396). The award, effective March 10, 2025 through February 28, 2030, supports research to identify novel genes and mechanisms underlying therapy resistance and relapse in acute myeloid leukemia (AML). The research aims to functionally validate candidate genes from prior single-cell RNA sequencing and CRISPR screens in order to better understand...
The National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), awarded a $217,863 Project Grant (R21CA297312) to the University of Colorado-Denver. The grant, effective from Dec 1, 2024 through Nov 30, 2026, supports research to compare natural killer (NK) cell profiles within melanoma tumors and pregnancy. The research aims to identify biomarkers that can predict risk of disease progression and response to immune-checkpoint blockade therapy for melanoma...
The National Cancer Institute (NCI), under the Federal Grant Program "Cancer Treatment Research" (CFDA 93.395), awarded a Project Grant of $402,600.00 to the Sloan-Kettering Institute for Cancer Research. The grant supports the development of novel chimeric antigen receptor (CAR) T-cell therapies targeting the U5 snRNP complex for the treatment of acute myeloid leukemia (AML). The key objectives are to (1) evaluate the efficacy and safety of U5 snRNP200-targeted CAR T cells,...
The National Cancer Institute (NCI) awarded a $237,023 Project Grant (CFDA 93.396 - Cancer Biology Research) to the Icahn School of Medicine at Mount Sinai. The 3-year award (3/1/2025 - 2/29/2028) will fund the development and optimization of a scalable, high-throughput single-cell method (SHARE-ME-SEQ) to simultaneously profile gene expression, chromatin accessibility, and DNA methylation in acute myeloid leukemia (AML) samples. Researchers will apply this technology to analyze bone marrow...
The National Cancer Institute (NCI) awarded a $107,010 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The Washington University in St. Louis. The grant supports research to dissect the mechanistic differences between two types of gain-of-function events in the EZH2 gene that drive non-Hodgkin lymphoma, a common type of cancer. The research aims to determine if the EZH2Y641F mutation and EZH2 overexpression are functionally equivalent or distinct, and whether they drive...